Roberta Zappasodi1,2, Jedd D Wolchok1,2,3,4, Taha Merghoub5,6,7. 1. Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 2. Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 4. Weill Cornell Medicine, New York, NY, 10065, USA. 5. Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. merghout@mskcc.org. 6. Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. merghout@mskcc.org. 7. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. merghout@mskcc.org.
Abstract
PURPOSE OF REVIEW: Despite the clinical successes of immune checkpoint blockade across multiple tumor types, many patients do not respond to these therapies or become resistant after an initial response. This underscores the need to improve our understanding of the molecular determinants of response to guide more personalized and rational utilization of these therapies. Here, we describe available biomarkers of checkpoint blockade activity by classifying them into four major categories: tumor-intrinsic, immune microenvironmental, host-related, and dynamic factors. RECENT FINDINGS: The clinical experience accumulated thus far with checkpoint blockade now offers the opportunity to comprehensively study the molecular and immune features associated with response. This is yielding a growing set of biomarkers whose integration will be key to more accurately predict clinical outcome. We propose a model for systematic assessment of available baseline and dynamic biomarkers in relationship with patients' outcomes. This will improve our understanding of the tumor-immune interactions and dynamics that predict a clinical response and will provide key information to develop more personalized and effective treatment strategies.
PURPOSE OF REVIEW: Despite the clinical successes of immune checkpoint blockade across multiple tumor types, many patients do not respond to these therapies or become resistant after an initial response. This underscores the need to improve our understanding of the molecular determinants of response to guide more personalized and rational utilization of these therapies. Here, we describe available biomarkers of checkpoint blockade activity by classifying them into four major categories: tumor-intrinsic, immune microenvironmental, host-related, and dynamic factors. RECENT FINDINGS: The clinical experience accumulated thus far with checkpoint blockade now offers the opportunity to comprehensively study the molecular and immune features associated with response. This is yielding a growing set of biomarkers whose integration will be key to more accurately predict clinical outcome. We propose a model for systematic assessment of available baseline and dynamic biomarkers in relationship with patients' outcomes. This will improve our understanding of the tumor-immune interactions and dynamics that predict a clinical response and will provide key information to develop more personalized and effective treatment strategies.
Entities:
Keywords:
Gut microbiota; Immune checkpoint; Immunotherapy; Neoantigens; Response biomarkers; T cells
Authors: Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz Journal: J Clin Oncol Date: 2017-04-25 Impact factor: 44.544
Authors: Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp Journal: Blood Date: 2010-07-13 Impact factor: 22.113
Authors: Alessandro Prestipino; Alica J Emhardt; Konrad Aumann; David O'Sullivan; Sivahari P Gorantla; Sandra Duquesne; Wolfgang Melchinger; Lukas Braun; Slavica Vuckovic; Melanie Boerries; Hauke Busch; Sebastian Halbach; Sandra Pennisi; Teresa Poggio; Petya Apostolova; Pia Veratti; Michael Hettich; Gabriele Niedermann; Mark Bartholomä; Khalid Shoumariyeh; Jonas S Jutzi; Julius Wehrle; Christine Dierks; Heiko Becker; Annette Schmitt-Graeff; Marie Follo; Dietmar Pfeifer; Jan Rohr; Sebastian Fuchs; Stephan Ehl; Frederike A Hartl; Susana Minguet; Cornelius Miething; Florian H Heidel; Nicolaus Kröger; Ioanna Triviai; Tilman Brummer; Jürgen Finke; Anna L Illert; Eliana Ruggiero; Chiara Bonini; Justus Duyster; Heike L Pahl; Steven W Lane; Geoffrey R Hill; Bruce R Blazar; Nikolas von Bubnoff; Erika L Pearce; Robert Zeiser Journal: Sci Transl Med Date: 2018-02-21 Impact factor: 17.956
Authors: Pei-Ling Chen; Whijae Roh; Alexandre Reuben; Zachary A Cooper; Christine N Spencer; Peter A Prieto; John P Miller; Roland L Bassett; Vancheswaran Gopalakrishnan; Khalida Wani; Mariana Petaccia De Macedo; Jacob L Austin-Breneman; Hong Jiang; Qing Chang; Sangeetha M Reddy; Wei-Shen Chen; Michael T Tetzlaff; Russell J Broaddus; Michael A Davies; Jeffrey E Gershenwald; Lauren Haydu; Alexander J Lazar; Sapna P Patel; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Scott E Woodman; Luis M Vence; Ignacio I Wistuba; Rodabe N Amaria; Lawrence N Kwong; Victor Prieto; R Eric Davis; Wencai Ma; Willem W Overwijk; Arlene H Sharpe; Jianhua Hu; P Andrew Futreal; Jorge Blando; Padmanee Sharma; James P Allison; Lynda Chin; Jennifer A Wargo Journal: Cancer Discov Date: 2016-06-14 Impact factor: 39.397
Authors: Derek Ng Tang; Yu Shen; Jingjing Sun; Sijin Wen; Jedd D Wolchok; Jianda Yuan; James P Allison; Padmanee Sharma Journal: Cancer Immunol Res Date: 2013-07-31 Impact factor: 11.151
Authors: R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: Bradley C Carthon; Jedd D Wolchok; Jianda Yuan; Ashish Kamat; Derek S Ng Tang; Jingjing Sun; Geoffrey Ku; Patricia Troncoso; Christopher J Logothetis; James P Allison; Padmanee Sharma Journal: Clin Cancer Res Date: 2010-05-11 Impact factor: 12.531
Authors: Ahmad A Tarhini; Howard Edington; Lisa H Butterfield; Yan Lin; Yongli Shuai; Hussein Tawbi; Cindy Sander; Yan Yin; Matthew Holtzman; Jonas Johnson; Uma N M Rao; John M Kirkwood Journal: PLoS One Date: 2014-02-03 Impact factor: 3.240
Authors: Jian Ye; Bradley N Mills; Tony Zhao; Booyeon J Han; Joseph D Murphy; Ankit P Patel; Carl J Johnston; Edith M Lord; Brian A Belt; David C Linehan; Scott A Gerber Journal: Cancer Immunol Res Date: 2019-11-12 Impact factor: 11.151
Authors: Inna Serganova; Sanjukta Chakraborty; Samuel Yamshon; Yusuke Isshiki; Ryan Bucktrout; Ari Melnick; Wendy Béguelin; Roberta Zappasodi Journal: Front Cell Dev Biol Date: 2022-01-07